Sale!

ABCD1 Gene AdrenoleukodystrophyAdrenomyeloneuropathy Genetic Test

4,400 د.إ

-21%

The ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test is a specialized diagnostic procedure offered at DNA Labs UAE, designed to detect mutations in the ABCD1 gene. These mutations are responsible for a range of genetic disorders, including Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN), which are X-linked conditions affecting the nervous system and adrenal glands. The test, priced at 4400 AED, involves analyzing the patient’s DNA to identify any abnormalities in the ABCD1 gene that could lead to these conditions. This test is crucial for early detection and management of ALD and AMN, potentially guiding treatment options and family planning decisions. DNA Labs UAE employs advanced genetic testing technologies to ensure accurate and reliable results, offering a critical resource for individuals and families at risk of these genetic disorders.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test

Test Name: ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test

Components: ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test

Price: 4400.0 AED

Sample Condition: Blood

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy.

Test Details: Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN) are X-linked genetic disorders caused by mutations in the ABCD1 gene. ALD primarily affects the nervous system and the adrenal glands, while AMN primarily affects the spinal cord and peripheral nerves. Both disorders are characterized by the accumulation of very long-chain fatty acids (VLCFAs) in tissues and organs, leading to damage and dysfunction.

NGS (Next-Generation Sequencing) genetic testing is a method used to identify mutations in the ABCD1 gene. This test involves sequencing the entire coding region of the gene, as well as adjacent non-coding regions, to identify all possible mutations. NGS testing is more comprehensive than traditional Sanger sequencing, which only targets specific regions of the gene.

NGS genetic testing for ALD/AMN is typically performed on a blood sample. The test results can confirm a diagnosis of ALD or AMN in individuals with symptoms, or identify carriers of the disease in asymptomatic individuals. Early diagnosis is critical for ALD, as it allows for early intervention and treatment to prevent or delay the onset of symptoms.

Overall, NGS genetic testing for ALD/AMN can provide important information for individuals and families affected by these disorders, including diagnosis, prognosis, and genetic counseling.

Test Name ABCD1 Gene AdrenoleukodystrophyAdrenomyeloneuropathy Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy
Test Details

Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN) are X-linked genetic disorders caused by mutations in the ABCD1 gene. ALD primarily affects the nervous system and the adrenal glands, while AMN primarily affects the spinal cord and peripheral nerves. Both disorders are characterized by the accumulation of very long-chain fatty acids (VLCFAs) in tissues and organs, leading to damage and dysfunction.

NGS (Next-Generation Sequencing) genetic testing is a method used to identify mutations in the ABCD1 gene. This test involves sequencing the entire coding region of the gene, as well as adjacent non-coding regions, to identify all possible mutations. NGS testing is more comprehensive than traditional Sanger sequencing, which only targets specific regions of the gene.

NGS genetic testing for ALD/AMN is typically performed on a blood sample. The test results can confirm a diagnosis of ALD or AMN in individuals with symptoms, or identify carriers of the disease in asymptomatic individuals. Early diagnosis is critical for ALD, as it allows for early intervention and treatment to prevent or delay the onset of symptoms.

Overall, NGS genetic testing for ALD/AMN can provide important information for individuals and families affected by these disorders, including diagnosis, prognosis, and genetic counseling.